BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Fuji
Cipla
Farmers Insurance
Cantor Fitzgerald
McKinsey
Julphar
Citi
Covington
Cerilliant

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,877,708

« Back to Dashboard

Which drugs does patent 8,877,708 protect, and when does it expire?

Patent 8,877,708 protects CYCLOSET and is included in one NDA.

This patent has eight patent family members in six countries.
Summary for Patent: 8,877,708
Title:Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI)
Assignee: VeroScience, LLC (Tiverton, RI)
Application Number:13/375,810
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,877,708

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,877,708

PCT Information
PCT FiledJune 07, 2010PCT Application Number:PCT/US2010/037605
PCT Publication Date:December 09, 2010PCT Publication Number: WO2010/141938

Non-Orange Book US Patents Family Members for Patent 8,877,708

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,352,025 Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,877,708

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2012529434 ➤ Subscribe
Japan 5883382 ➤ Subscribe
European Patent Office 2437732 ➤ Subscribe
China 102458376 ➤ Subscribe
Brazil PI1009619 ➤ Subscribe
Japan 2016026168 ➤ Subscribe
Australia 2010256366 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2010141938 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Merck
US Department of Justice
Teva
McKesson
Accenture
Johnson and Johnson
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot